American Association for Cancer Research
Browse
21598290cd120210-sup-f1-5_1445k.pdf (1.41 MB)

Supplementary Figures 1-5 from FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

Download (1.41 MB)
journal contribution
posted on 2023-04-03, 20:28 authored by Vito Guagnano, Audrey Kauffmann, Simon Wöhrle, Christelle Stamm, Moriko Ito, Louise Barys, Astrid Pornon, Yao Yao, Fang Li, Yun Zhang, Zhi Chen, Christopher J. Wilson, Vincent Bordas, Mickaël Le Douget, L. Alex Gaither, Jason Borawski, John E. Monahan, Kavitha Venkatesan, Thomas Brümmendorf, David M. Thomas, Carlos Garcia-Echeverria, Francesco Hofmann, William R. Sellers, Diana Graus-Porta

PDF file - 1.4MB, Response to NVP-BGJ398; FGFR pathway modulation by NVP-BGJ398; NVP-BGJ398 - predictive features; FGFR2-c3 mRNA expression in cell lines and FGFR2 DNA copy number in tumors; FGF19 DNA copy number in CCLE cell lines and FGFR3 DNA copy number versus transcript expression in bladder cancer cell lines

History

ARTICLE ABSTRACT

Patient stratification biomarkers that enable the translation of cancer genetic knowledge into clinical use are essential for the successful and rapid development of emerging targeted anticancer therapeutics. Here, we describe the identification of patient stratification biomarkers for NVP-BGJ398, a novel and selective fibroblast growth factor receptor (FGFR) inhibitor. By intersecting genome-wide gene expression and genomic alteration data with cell line–sensitivity data across an annotated collection of cancer cell lines called the Cancer Cell Line Encyclopedia, we show that genetic alterations for FGFR family members predict for sensitivity to NVP-BGJ398. For the first time, we report oncogenic FGFR1 amplification in osteosarcoma as a potential patient selection biomarker. Furthermore, we show that cancer cell lines harboring FGF19 copy number gain at the 11q13 amplicon are sensitive to NVP-BGJ398 only when concomitant expression of β-klotho occurs. Thus, our findings provide the rationale for the clinical development of FGFR inhibitors in selected patients with cancer harboring tumors with the identified predictors of sensitivity.Significance: The success of a personalized medicine approach using targeted therapies ultimately depends on being able to identify the patients who will benefit the most from any given drug. To this end, we have integrated the molecular profiles for more than 500 cancer cell lines with sensitivity data for the novel anticancer drug NVP-BGJ398 and showed that FGFR genetic alterations are the most significant predictors for sensitivity. This work has ultimately endorsed the incorporation of specific patient selection biomakers in the clinical trials for NVP-BGJ398. Cancer Discov; 2(12); 1118–33. ©2012 AACR.Read the Commentary on this article by Loch and Pollock, p. 1081This article is highlighted in the In This Issue feature, p. 1065